Smoking among Chinese patients with schizophrenia

Australian and New Zealand Journal of Psychiatry

Volumn 30, Issue 3, 1996, Pages 350-353

  Chong, Siow Ann ^a   Choo, Hock Lai ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; NICOTINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DEMOGRAPHY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; ONSET AGE; PREVALENCE; RACE DIFFERENCE; RATING SCALE; SCHIZOPHRENIA; SMOKING;

EID: 0030015779     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.3109/00048679609064998     Document Type: Article

References (31)

1. De Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. American Journal of Psychiatry 1995; 152:453-455.
2. Goff DC, Henderson DC, Amico E Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects American Journal of Psychiatry 1992; 149:1189-1194.
3. Gopalaswamy AK, Morgan R. Smoking in chronic schizophrenia [letter]. British Journal of Psychiatry 1986; 149:523.
4. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatrie outpatients. American Journal of Psychiatry 1986; 143:993-997.
5. Masterson E, O'Shea B. Smoking and malignancy in schizophrenia. British Journal of Psychiatry 1984; 145:429-432.
6. Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio PL Cigarette smoking and neuroleptic-induced parkinsonism. Biological Psychiatry 1990; 28:502-508.
7. Vinarova E, Vinar O, Kalvach Z. Smokers need higher doses of neuroleptic drugs. Biological Psychiatry 1984; 19: 1265-1268.
8. Jann MW, Saklad SR, Ereshesky L, Richards AL, Harrington CA, Davis CM. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986; 90:468-470.
9. Miller LG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clinical Pharmacology 1990; 9:125-135.
10. Rudorfer MV. Pharmacokinetics of psychotropic drugs in special populations. Journal of Clinical Psychiatry 1993; 59 (Suppl. 9): 50-54.
11. Potkin SG, Shen Y, Pardes H et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Research 1984; 12:167-172.
12. Bertilsson L, Lou YQ, Du YL et al. Pronounced differences between native Chinese and Swedish populations m the polymorphic hydroxylations of debrisoquone and S-mephenytoin. Clinical Pharmacology and Therapeutics 1992; 51:388-392.
13. Lou YC, Ying L, Bertilsson, Sjoqvist F. Low frequency of debrisoquine hydroxylation in a native Chinese population. Lancet 1987; 2:852
14. Lee EJD, Yeoh PN, Gong NH. Oxidation phenotyping in Chinese and Malay populations. Clinical Experimental Pharmacology and Physiology 1988; 15:889-891.
15. Kalow W. Genetic variation in the human hepatic cytochrome P450 system. European Journal of Clinical Pharmacology 1987; 31:633-641.
16. Binder RL, Levy R. Extrapyramidal reactions in Asians. American Journal of Psychiatry 1981; 138:1241-1244.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington: American Psychiatric Association, 1987.
18. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962; 10:799-812.
19. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970; 45(Suppl. 212):11-19.
20. Davis JM. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 1976; 33:858-861.
21. Lader M, Herrington R. Psychoses and antipsychotic medications. In: Biological treatments in psychiatry. Oxford: Oxford University Press, 1990:216-257.
22. Research and Evaluation Department, Ministry of Health, Singapore. National health survey 1992. Research and Evaluation Department, Ministry of Health, Singapore, 1993.
23. Anderson K, Fuxe K, Agnati LF. Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Acta Physiologica Scandinavica 1981; 112:345-347.
24. Grenhoff J, Aston, Jones G, Svensson TH. The nicotinic effects on the firing pattern midbrain dopamine neurons. Acta Physiologica Scandinavica 1986; 128:351-358.
25. Wise RA, Bozarth MA. Brain reward circuitry: four circuit elements 'wired' in apparent series. Brain Research Bulletin 1984; 12:203-208.
26. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242:712-723.
27. Glassman AH. Cigarette smoking: implications for psychiatric illness. American Journal of Psychiatry 1993; 150:546-553.
28. MacKay AVP. Positive and negative schizophrenic symptoms and the role of dopamine: discussion, 1. British Journal of Psychiatry 1980; 137:379-383.
29. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase in synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences (USA) 1988; 85:5274-5278.
30. Gardner EL Brain reward mechanisms. In: Lowinson JH, Ruiz P, Millman RB, eds. Comprehensive textbook of substance abuse 2nd ed. Baltimore' Williams and Wilkins, 1992.
31. Mortensen PB, Juel K Mortality and causes of death in first admitted schizophrenia patients. British Journal of Psychiatry 1993; 163:183-189.